Cibc World Market Inc. Buys New Shares in Regeneron Pharmaceuticals, Inc. $REGN

Cibc World Market Inc. bought a new position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in the second quarter, Holdings Channel.com reports. The firm bought 21,806 shares of the biopharmaceutical company’s stock, valued at approximately $13,597,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in REGN. OMERS ADMINISTRATION Corp purchased a new stake in Regeneron Pharmaceuticals during the 2nd quarter valued at about $6,297,000. Osmosis Investment Management UK Ltd acquired a new position in shares of Regeneron Pharmaceuticals in the second quarter valued at about $1,757,000. Sanctuary Advisors LLC purchased a new position in shares of Regeneron Pharmaceuticals in the second quarter worth about $24,894,000. Biondo Investment Advisors LLC purchased a new position in shares of Regeneron Pharmaceuticals in the second quarter worth about $6,990,000. Finally, Solstein Capital LLC acquired a new stake in shares of Regeneron Pharmaceuticals during the second quarter worth about $43,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on the stock. Wall Street Zen upgraded shares of Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 15th. Royal Bank Of Canada lifted their price objective on shares of Regeneron Pharmaceuticals from $696.00 to $737.00 and gave the company a “sector perform” rating in a research note on Friday, July 31st. Barclays dropped their price objective on shares of Regeneron Pharmaceuticals from $923.00 to $917.00 and set an “overweight” rating on the stock in a report on Thursday, April 30th. Piper Sandler cut their price objective on shares of Regeneron Pharmaceuticals from $855.00 to $854.00 and set an “overweight” rating on the stock in a research note on Thursday, July 9th. Finally, Sanford C. Bernstein raised shares of Regeneron Pharmaceuticals to a “hold” rating in a report on Wednesday, July 29th. Sixteen investment analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company’s stock. According to MarketBeat.com, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $801.70.

Regeneron Pharmaceuticals Trading Down 0.7%

Shares of NASDAQ:REGN opened at $828.50 on Tuesday. The company has a current ratio of 3.34, a quick ratio of 2.78 and a debt-to-equity ratio of 0.06. Regeneron Pharmaceuticals, Inc. has a 12-month low of $541.00 and a 12-month high of $847.00. The business has a 50 day moving average of $701.36 and a two-hundred day moving average of $716.94. The company has a market capitalization of $85.30 billion, a PE ratio of 20.48, a PEG ratio of 1.42 and a beta of 0.22.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $14.29 EPS for the quarter, topping analysts’ consensus estimates of $10.16 by $4.13. The business had revenue of $4.29 billion for the quarter, compared to analysts’ expectations of $3.82 billion. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. The business’s revenue was up 16.7% on a year-over-year basis. During the same quarter last year, the company earned $12.81 EPS. As a group, analysts forecast that Regeneron Pharmaceuticals, Inc. will post 44.25 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, August 31st. Investors of record on Tuesday, August 18th will be given a dividend of $0.94 per share. This represents a $3.76 annualized dividend and a yield of 0.5%. The ex-dividend date is Tuesday, August 18th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is currently 9.29%.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, Director Huda Y. Zoghbi sold 800 shares of Regeneron Pharmaceuticals stock in a transaction on Monday, August 10th. The shares were sold at an average price of $800.00, for a total value of $640,000.00. Following the completion of the transaction, the director owned 1,703 shares of the company’s stock, valued at approximately $1,362,400. The trade was a 31.96% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kathryn Guarini sold 400 shares of the company’s stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $800.00, for a total transaction of $320,000.00. Following the completion of the transaction, the director owned 603 shares of the company’s stock, valued at approximately $482,400. This trade represents a 39.88% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 1,400 shares of company stock valued at $1,090,030. Corporate insiders own 6.97% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.